the rosenfeld cancer center at abington hospital ... · cancer research the rosenfeld cancer center...

THE ROSENFELD CANCER CENTER AT ABINGTON HOSPITAL – JEFFERSON HEALTH

2 0 1 6 A N N U A L R E P O R T

The mission of Abington – Jefferson Health’s Rosenfeld Cancer Center

is to promote a coordinated, multidisciplinary cancer program that

provides high-quality, accessible, compassionate and cost-effective care

to our community.

T A B L E O F C O N T E N T S

Program Achievements ....................................................................................................................................................2

Cancer Care Services ........................................................................................................................................................3

Cancer Programs ...............................................................................................................................................................7

Cervical Cancer 2010–2012 Data for 2015 Patient Care Evaluation Analysis ................................................... 10

Summary of All Cancer Sites ......................................................................................................................................... 11

Quality Indicators .............................................................................................................................................................13

The annual report was approved in November 2016 by the Cancer Committee of Abington – Jefferson Health.

two

1. The Rosenfeld Cancer Center

continued operations in 2015 with

full service in medical oncology,

gynecologic oncology, radiation

oncology and surgical oncology.

2. Two patient care evaluations

were performed. This included a

longitudinal care study of Prostate

Cancers, 2008 data entered into the

tumor registry, results of which were

reported in the 2015 Annual Report.

In addition, a quality of care study of

Follicular Lymphoma was reported

utilizing the NCCN treatment guide

lines for the 20122013 data. In

addition, two patient care enhance

ment projects were performed in

2015. A program enhancement

resulting from these studies included

Psychosocial Distress Screening –

Consistent screening of patients

with new cancer diagnoses at

pivotal visits. All of these evalu ations

and projects were first approved by

the AJH Cancer Committee and

then reviewed by the committee

after completion.

3. Physician and nursing education

programs continued in 2015. These

included a monthly oncology journal

club, an invited oncology professor

program with updates on new

developments in cancer care and

presentations at the annual update

for primary care physicians as well

as monthly department meetings.

In January 2015, a Grand Rounds

was presented on “Prostate Cancer:

The Past, Present and Future.”

4. Community cancer screening

programs continued with planning

and execution by the Abington –

Jefferson Health Cancer Education

Committee. These included breast,

skin and prostate cancer screenings.

Community education programs

were based on the population and

included, but not limited to, high

school children and retirement

communities.

5. Weekly cancer conferences

continued in 2015 with disease

specific conferences in breast

cancer, lymphoma and leukemia,

GI malignancies, GU malignancies,

GYN Oncologic, head and neck,

pulmonary malignancies, endo crine

malignancies, neurological, thyroid

and general conferences for all

other malignancies.

6. A cancer risk assessment program

continued in 2015 for breast,

ovarian, endometrial and colon

cancers with steadily increasing

participation by members of the

community at no cost.

7. In 2015, 33 patients were entered on

NRG Oncology trials, two industry

sponsored and 124 on inhouse

medical protocols. In addition, 23

patients were entered on GOG or

Gyn Oncology inhouse protocols.

A total of 182 patients participated

in cancer clinical research protocols

during the past year.

Program Achievements in 2015-2016

Cancer Research

The Rosenfeld Cancer Center

participates in clinical trials in the

areas of prevention and treatment

primarily through NRG Oncology, a

national cooperative group under the

auspices of the National Cancer

Institute (NCI). Parviz Hanjani, MD is

the principal investigator and Willard

Andrews, MD and Wayne Pinover, DO

are coprincipal investigators. In

addition, several industry sponsored

trials are conducted annually. The

Center for Clinical Research, under the

direction of Susan Nolte, CRNP, PhD,

provides regulatory and research

oversight for all oncology clinical trials.

Surgical Oncology

Surgery is a mainstay in the treatment

of cancer. Abington – Jefferson Health

offers a full range of options in general

surgery, neurosurgery, oral/maxillofacial

surgery, orthopaedics, otolaryngology,

plastic and reconstructive surgery,

thoracic surgery, urology and full

colorectal service. Our comprehensive

cancer program includes the use

of the daVinci Robot for numerous

surgical procedures within the thoracic,

gynecologic and urologic specialties.

Gynecologic Oncology

The management of gynecologic

cancer patients and the teaching of

residents and medical students are

provided by the Hanjani Institute for

Gynecologic Oncology at Abington –

Jefferson Health. The Institute is under

the direction of Mark Shahin, MD,

boardcertified gynecologic oncologist.

In addition to the Director are three

other physicians, Parviz Hanjani, MD,

Mitchell Edelson, MD, and Elizabeth

R. Burton, MD, all boardcertified

gynecologic oncologists.

The Institute is actively involved in

extensive clinical research and is a

full member of the NRG Oncology.

The Institute is a major contributor of

clinical research to NRG Oncology

with an outstanding record and is

highly respected. Susan Nolte, CRNP,

PhD, is Director of the Center for

Clinical Research, promoting research

throughout the hospital and overseeing

all of the research activities in the

Institute. Three fulltime registered

nurses are involved in clinical research,

inhouse and NRG Oncology protocols

and all aspects of patient care.

Radiation Oncology

The Division of Radiation Oncology

offers stateofthescience care using

the most contemporary technology

staffed by two boardcertified

radiation oncologists.

Prostate Brachytherapy

Prostate brachytherapy, a program

of ultrasoundguided percutaneous

implantation of radioactive iodine or

palladium, is being used widely for

eligible patients with early stage

prostate cancer.

Pain Management Services

The Department of Anesthesiology

provides both inpatient and outpatient

Cancer Care Services

three

Mark McKeeColorectal Cancer Survivor


four

.

pain management services for complex

oncologic needs.

Breast Imaging Services

The Mary T. Sachs Breast Center is

located at Abington Health Center –

Willow Grove. Tomosynthesis

mammograms are available at all

Abington – Jefferson Health locations,

as well as preoperative needle

localization. Stereotactic breast

biopsies and ultrasoundguided

biopsies are performed on the same

campus to provide consolidated breast

diagnostic procedures. Magnetic

resonance imaging of the breast is

available at the hospital main campus.

Nuclear Medicine

Basic nuclear medicine diagnostic

examinations involved in the detection

and followup of cancer patients are

performed. These studies include bone

scans, PET scans, thyroid scans, thyroid

wholebody imaging, liver scans, and

gallium, sestamibi, and thallium tumor

imaging studies.

Interventional Radiology

The Department of Radiology

continues to offer the most current

diagnostic, therapeutic and palliative

technologies for care of cancer patients

through its section of Interventional

Radiology. Interventional Radiology

provides vascular access, diagnostic

biopsies, thrombolytic therapy and

drainage or stenting of pathways

such as blood vessels or bile ducts

compromised by tumors.

Cancer Rehabilitation

The comprehensive cancer rehabili

tation program is designed to provide all

Abington – Jefferson Health inpatients

and outpatients with comprehensive,

interdisciplinary care for impairments

related to the direct and indirect effects

of cancer and its treatment. In addition,

the prevention and treatment of post

surgical lymphedema is carried out in

a specialized program.

Inpatient Oncology Unit

Abington – Jefferson Health provides

a multidisciplinary approach to the

treatment of patients in its 27 private

bed inpatient Oncology Unit. The team

consists of medical and gynecological

oncologists, chemotherapycertified

oncology nurses, oncology social

workers, an oncology case manager, an

oncology clinical dietitian and chaplains.

Palliative Care

The Palliative Care Service is available

to patients at Abington – Jefferson

Health with advanced medical illness,

especially chronic and progressive life

limiting conditions. This specialized

team of physicians, nurses, social

workers, a pharmacist and a chaplain

focuses on meeting patients’ and

families’ medical, emotional and

spiritual needs while working with the

entire healthcare team. The team

provides expert pain and symptom

management and focuses on open

communication in difficult situations,

as well as recognition of individual

choices throughout serious illness. The

expansion of palliative care services will

Shannon Hayes Breast Cancer Survivor

begin this upcoming year reaching out

to patients and their families in long

term care settings. Palliative Care is

provided to patients at home under

their home health care benefit

by specially trained nurses in pain

and symptom management and

social workers for support and

community resources.

Hospice Program

The Hospice Program of Abington –

Jefferson Health provides skilled and

supportive hospice care services to

patients and their families. Care is

primarily based in the person’s home,

enabling the person to remain at

home with care directed toward

comfort measures. Inpatient level

of care for symptom management

is provided at Abington Hospital –

Jefferson Health in a dedicated four

bed unit and inpatient and residential

hospice care is provided at Abington

Hospice at Abington Health Center –

Warminster with 19 beds. “Safe Harbor,”

a specialized bereavement care

program, is available for children,

adolescents and their families.

Cancer Registry

The Cancer Registry at Abington –

Jefferson Health is an information

system designed for the collection,

management and analysis of data

on persons with the diagnosis of a

malignant or neoplastic disease. All

information obtained is forwarded

to the Pennsylvania Cancer Registry

and the National Cancer Data Base.

A total of 1,982 abstracts were

submitted for 2015.

Cancer Evaluation Services

The Rosenfeld Cancer Center’s

Evaluation Services provide a team

approach to prospective treatment

planning at the initial time of diagnosis

of a malignancy and at any point along

the continuum of care.

Abington – Jefferson Health offers

evaluation services free to patients and

to members of the community who

are not patients of Abington – Jefferson

Health, yet are interested in the team’s

opinion for the following malignancies:

• Breast

• Gastrointestinal/Colorectal

• Head and Neck

• Hepatobiliary

• Gynecologic Oncology

• Lymphoma/Leukemia

• Pulmonary

• Solid Tumor

• Neurological

• Thyroid

• Urological

Breast, Ovarian and Colon Cancer

Risk Assessment and Genetic Testing

Abington – Jefferson Health’s Rosenfeld

Cancer Center offers the Breast, Ovarian

and Colon Cancer Risk assessment

program for patients and members of

the community who may be at risk for

developing breast, ovarian, endometrial

or colon cancer. Patients and families

participating in the program may be

eligible for highrisk surveillance and

recommendations for studies and

genetic testing.

Cancer Helpline

In 1995, Abington – Jefferson Health

instituted a Helpline, 1-800-405-HELP.

With this one number, patients are able

to access any of our navigators or obtain

a physician referral.

Cancer Education and

Screening Activities

The Abington – Jefferson Health Cancer

Education Committee, a subcommittee

of the Cancer Committee, organizes

and supervises a vast range of programs

in the areas of staff, patient and

community cancer education,

screening and early detection. The

members of this multidisciplinary,

institutionwide committee volunteer

their time and expertise to offer

the community these valuable,

free services.

The cancer sites chosen reflect both

the most frequently occurring cancers

in the community and those for which

there are lowcost, effective screening

techniques.

• Breast cancer education and

screening programs

• Prostate cancer screening programs

• Skin cancer screening

• Professional education

five

six

Cancer Support Services

A number of support groups and

services are available to patients and

their families to assist them in coping

with the psychosocial impact of living

with cancer. There is a great need and

demand for these services throughout

the continuum of diagnosis, treatment,

disease management, survivorship and

terminal care. These services include:

• Oncology Social Work

• Oncology Dietician

• Look Good, Feel Better – A skin and

cosmetic makeover session for

cancer patients cosponsored by

the American Cancer Society.

• Pastoral Care Services

• Grief Recovery Support Groups

• Reach to Recovery

• Man to Man

• Cancer Support Community

Through our partnership with the

Cancer Support Community, we are

able to offer support services on our

Abington Hospital campus and refer to

the Gilda’s Club location in Warminster.

Patients have access to services

during the day and evening. In

addition to support groups, Gilda’s

Club offers nutritional counseling,

stress management, relaxation and

alternative services including yoga.

John HearyLung Cancer Survivor


Cancer Programs

Jennifer ShapbellStage III Colon Cancer Survivor

seven

Breast Program

The comprehensive Breast Cancer

program at Abington – Jefferson

Health incorporates the latest

technologies and treatments. Our

partnership with the Sidney Kimmel

Cancer Center at Jefferson has

expanded the options and expertise

available to our patients. The Mary T.

Sachs Breast Center offers the latest

in screening and diagnostic tools

including breast tomosynthesis and

breast MRI, as well as stereotactic and

MRI guided biopsies. Our dedicated

nurse navigator ensures seamless

appointments within the system,

as well as patient education and

support. Our radiologists, specialist

surgeons, medical oncologists and

radiation oncologists comprise a team

dedicated to forming an individualized

treatment plan for each patient. The

Breast Cancer Evaluation Service is

committed to developing a group

consensus treatment plan for patients.

Adherence to guidelines from the

National Comprehensive Cancer

Network and the Commission on

Cancer is considered key to providing

quality care, as well as access to state

oftheart clinical trials. Genetic testing

and molecular and targeted therapy

are available. Quality measures such

as radiation after breast conservation,

endocrine therapy for hormone

receptor positive cases and chemo

therapy for triple negative breast

cancers are closely monitored.

Colorectal Program

Abington – Jefferson Health’s

multidisciplinary program for

colorectal cancer includes specialty


radiation oncologists. Our GI Cancer

Evaluation Service incorporates these

physicians, as well as radiologists

and pathologists, to allow tailored

treatment plans. Our gastrointestinal

nurse navigator facilitates appointments

and provides patient education and

support resulting in exceptional

quality and continuity of care. Cancer

genomics, genetics and targeted

therapy are available. Specialty

gastroenterologists perform complex

procedures, and we offer the most

valuable imaging studies including

PET-CT and rectal MRI. Our partnership

with the Sidney Kimmel Cancer Center

at Jefferson has expanded the options

and expertise available to our patients.

Adherence to guidelines from the

National Comprehensive Cancer

Network and Commission on Cancer

is considered key to providing quality

care as well as access to stateofthe

art clinical trials. Quality measures are

closely monitored including adequate

lymph node harvest and appropriate

use of neoadjuvant or adjuvant

chemoradiation.

Lung Cancer program


multidisciplinary program for lung

cancer includes specialty thoracic


radiation oncologists. Our Lung Cancer

Evaluation Service incorporates these

physicians as well as radiologists,

pulmonologists and pathologists to

allow tailored treatment plans. Our

lung cancer nurse navigator facilitates

appointments and provides patient

education to support lung cancer

patients through this difficult process.

Specialty pulmonologists perform

complex procedures such as EBUS/

navigational bronchoscopy and we

offer the most valuable imaging studies

including PETCT. Radiation oncology

offers advanced stereotactic body

radiation for patients unable to be

considered for surgery. Interventional

radiology also offers radiofrequency

ablation and cryotherapy for these

patients as well. Our partnership with

the Sidney Kimmel Cancer Center at

Jefferson has expanded the options

and expertise available to our patients.

The use of cancer genomics, targeted

therapy and immunotherapy are all

available at The Rosenfeld Cancer

Center. Adherence to guidelines from

the National Comprehensive Cancer

Network and Commission on Cancer

is considered key to providing quality

care, as well as access to stateofthe

art clinical trials. Quality measures are

closely monitored including use of

adjuvant chemotherapy for resected

lung cancer and the use of neoadjuvant

or definitive chemoradiation for patients

with more advanced lung cancer.

Melanoma Program


multidisciplinary program for

melanoma includes dermatologists,

specialty surgeons, plastic surgeons,

medical oncologists and radiation

oncologists. Our Melanoma Evaluation

Service incorporates these physicians

as well as radiologists and pathologists,

to allow tailored treatment plans. Our

melanoma nurse navigator facilitates

appointments and provides patient

education resulting in exceptional

quality and continuity of care. Cancer

genomics, genetics and targeted

therapy are available, including

immunotherapy. Adherence to

guidelines from the National

Comprehensive Cancer Network and

Commission on Cancer is considered

key to providing quality care and access

to stateoftheart clinical trials. Our

partnership with the Sidney Kimmel

Cancer Center at Jefferson has

expanded the options and expertise

available to our patients. Quality

measures are closely monitored,

including the use of completion lymph

node dissection (after positive sentinel

node) and adequate lymph node

harvest during these procedures.

Cervical Cancer Program

Invasive cervical cancer remains a

significant threat to the lives of women

worldwide. Although it is largely

preventable, a quarter of million

women die of this disease every year

globally. The vast majority of deaths

occur in less developed regions of the

world, such as South East Asia, The

Western Pacific, India and Africa. In

these regions, access to pathology

services, skilled surgeons, radiation

machines and brachytherapy is

constrained. At least twothirds of

cervical cancer deaths occur in

women who had not been screened

regularly. If we improved screening

and HPV vaccination around the

world, we have an opportunity to

substantially decrease mortality from

cervical cancer. HPV 16/18 account

for at least twothirds of cervical

carcinomas in all continents. HPV 31,

33, 35, 45, 52, 58 are the next most

common types in cancer globally,

recognized as the most important

etiologic factor in this disease.

Cervical Cancer Analysis

At Abington Hospital – Jefferson

Health, 53 cases of invasive cervical

cancer were encountered and treated in

20102012 time intervals. Distribution

of cases by age mirrored that of NCDB

where 5.5% cases occurred in 2029

years, 7.4% in 8089 years, while the

majority (61.2%) were 4069 years

(Figure 1) . 53% of cases were stage I

(NCDB=43.5%), while 16.7% were

stage II (NCDB=14.8%) and 13% stage

III (NCDB=22.2%). Less than 15% of

cases were diagnosed as stage IV

(NCDB 13.7%) (Figure 2). Treatments

included surgery alone in 29.6%,

radiation alone in 7.4% and combination

of surgery and radiation in 5.6% of

cases. Chemoradiation was employed

in 35.2% cases typically appropriate

for stage II and III individuals (37%).

Chemoradiation was also administered

in combination with surgery (pre or

Cancer Programs

eight

Beth DoughertyCervical Cancer Survivor

nine

post) in 9.3% of cases typically due

to high risk factors. In stage IA1 cases,

surgery included two conizations

(fertility sparing), five simple

hysterectomies and three radical

hysterectomies. In stages IA2IB1 where

surgery (Radical Hysterectomy) was

offered, twothirds of the procedures

were minimally invasive.

The American Society of Clinical

Oncology (ASCO) in 2016 has issued

clinical practice guidelines on invasive

cervical cancer. Key recommendations

include: 1. In basic settings where

patients cannot be treated with

radiation therapy, extrafascial

hysterectomy either alone or after

neoadjuvant chemotherapy may be

an option for women with stage IA1

to IVA cervical cancer. 2. Concurrent

radiotherapy and chemotherapy

followed by brachytherapy is standard

in enhanced and maximal setting for

women with stage IB to IVA disease.

The panel stresses the addition of

lowdose chemotherapy during

radiotherapy. 3. In limited resource

settings where there is no brachytherapy,

the ASCO expert panel recommends

extrafascial hysterectomy or its

modification for women who have

residual tumor two to three months

after concurrent chemoradiotherapy

and additional boost. 4. Palliative

radio therapy should be used in cases

where curative intent cannot be offered

to relief symptoms of pain and bleeding.

5. For patients with stage IV disease or

recurrence, platinum based chemo

therapy (at least single agent, but

preferably combination) should

be provided.

ten

Cervical Cancer

Distribution by Age 2010–2012

Percentage of All Cases 30

25

20

15

10

5

0 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+

Distribution by Stage 2010–2012

Percentage of All Cases

Distribution by First Course Treatment 2010–2012


60

50

40

30

20

10

0

40

35

30

25

20

15

10

5

0

I II III IV Unknown

Surg XRT Srg/XRT XRT/Chm Srg/XRT/Chm Observation None

n AJH

n NCDB

Summary of All Cancer Sites 2015

Primary Site Analytic* Non-Analytic* Expired

Lip 2

Base of Tongue 3 1

Other Tongue 1 1 1

Palate 2

Other Mouth 3 1 1

Parotid Gland 4 1 1

Other Major Salivary Glands 1

Tonsil 2

Oropharynx 1

Nasopharynx 1

Pyriform Sinus 1

Hypopharynx 1 1 1

Esophagus 19 4 6

Stomach 16 4 3

Small Intestine 14 1 3

Colon 99 9 20

Rectosigmoid Junction 23 1 3

Rectum 40 2 3

Anus & Anal Canal 9 2

Liver & Intrahepatic Bile Duct 16 4 12

Gallbladder 4 1 2

Other Parts of Biliary Tract 10 6

Pancreas 43 4 23

Other Digestive Organs 2 1 2

Accessory Sinuses 2

Larynx 7 2

Bronchus & Lung 209 21 93

Thymus 2

Heart, Mediastinum & Pleura 7

Bones & Cartilage of Other 3 1 1

Hematopoietic & Reticuloendo System 74 15 19

eleven

** Analytic cases include all cancer patients diagnosed at Abington – Jefferson Health who received their first course of treatment here or elsewhere, and all

patients diagnosed elsewhere who received all or part of their first course of treatment here.

**Nonanalytic cases include cancer patients who were diagnosed elsewhere and received all of their first course of treatment elsewhere.

twelve

** Analytic cases include all cancer patients diagnosed at Abington – Jefferson Health who received their first course of treatment here or elsewhere, and all

patients diagnosed elsewhere who received all or part of their first course of treatment here.

**Nonanalytic cases include cancer patients who were diagnosed elsewhere and received all of their first course of treatment elsewhere.

Primary Site Analytic* Non-Analytic* Expired

Skin 78 24 3

Retroperitoneum & Peritoneum 9 4

Connective & Other Soft Tissue 9 3 1

Breast 323 39 7

Vulva 10 11

Vagina 2 1

Cervix Uteri 17 3 2

Corpus Uteri 144 3 11

Uterus, NOS 3 1

Ovary 50 2 10

Other Female Genital Organs 16 2

Placenta 3

Prostate Gland 129 13 3

Testis 4

Other Male Genital Organs 1

Kidney 52 5 8

Renal Pelvis 7

Ureter 7 1

Bladder 81 4 6

Eye & Adnexa 1 2

Meninges 40 2 4

Brain 55 4 15

Spinal Cord & Other CNS 7

Thyroid Gland 38 6 2

Adrenal Gland 2 1

Other Endocrine Glands 5

Other Sites 4

Lymph Nodes 50 3 9

Unknown Primary Site 13 4

Total 1,780 201 296

Quality Indicators

How We Compare to the National Cancer Database

In 1998, a Presidential Commission recommended the creation of a national forum in which health care’s many

stakeholders could, together, find ways to improve the quality and safety of America’s health care. This recommendation

led to the creation of the National Quality Forum (NQF), a private, notforprofit, public benefit corporation established

in 1999 to standardize healthcare quality measurement and reporting.

Established as a publicprivate partnership, the NQF has broad participation from all parts of the healthcare system,

including national, state, regional and local groups representing consumers, public and private purchasers, employees,

healthcare professionals, provider organizations, health plans and others involved in healthcare research or quality

improvement. Together the organizational members of the NQF work to promote a common approach to measuring

healthcare quality and fostering systemwide capacity for quality improvement.

The Commission on Cancer (CoC), through the Cancer Program Practice Reports (CP3R), promotes 12 quality indicators

utilizing the data submitted to the National Cancer Database. The data are from 2013.

CP3R and AJH’s Performance for Breast Cancer

Breast Conserving Surgery and Radiation Therapy


Chemotherapy in Hormone Receptor Negative Breast Cancer Patients


Radiation therapy is administrated within

one year (365 days) of diagnosis for women

under the age of 70 receiving breast

conserving surgery for breast cancer.

Abington – Jefferson Health’s compliance

with this standard is 90.1%.

100989694929088868482

90.1

95.8

92.9

AJH PA All CoC

100989694929088868482

100.0

95.293.0

AJH PA All CoC

Combination chemotherapy is considered

or administered within four months (120

days) of diagnosis for women under the

age of 70 with AJCC T1c N0M0, or Stage II

or III hormone receptor negative cancer.


with this standard is excellent at 100%,

compared to all CoC-approved programs’

norm of 93%.

thirteen

fourteen

Quality Indicators

Tamoxifen or third generation aromatase

inhibitor is considered or administered

within one year (365 days) of diagnosis for

women with AJCC T1c N0M0, or Stage II

or III hormone receptor positive cancer.


with this standard is favorable at 98.3%,


norm of 93%.

CP3R and AJH’s Performance for Breast Cancer

Tamoxifen or Third Generation Aromatase Inhibitor in Hormone Receptor Positive Breast Cancer Patients


100989694929088868482

98.3

95.793.0

AJH PA All CoC

Image or Palpation-guided Needle Biopsy Performed in Breast Cancer Diagnosis


100989694929088868482

94.0 93.091.2

AJH PA All CoC

Image or palpationguided needle biopsy is

performed to establish diagnosis of breast

cancer. Abington – Jefferson Health’s

compliance with this standard is above

the state’s average at 94%.

Radiation Therapy and Mastectomy


100989694929088868482

100.0

93.3

90.5

AJH PA All CoC

Radiation therapy is considered or

administered following any mastectomy

within one year of diagnosis of breast

cancer for women with four or more

positive regional lymph nodes. Abington –

Jefferson Health’s compliance with this

standard is excellent at 100%.

Breast Conserving Surgery


74727068666462605856

68.968.1

62.7

AJH PA All CoC

Breast conservation surgery rate for

women with AJCC clinical stage 0, I or II

breast cancer. Abington – Jefferson

Health’s compliance with this standard

is 6% higher than the CoC-approved

programs’ norm at 62.7%.

fifteen

CP3R and AJH’s Performance for Colon Cancer

Adjuvant Chemotherapy for Node Positive Patients


96949290888684828078

84.6

92.490.7

AJH PA All CoC

Adjuvant chemotherapy is considered or

administered within four months (120 days)

of diagnosis for patients under the age

of 80 with AJCC Stage III (lymph node

positive) colon cancer. Abington –

Jefferson Health’s compliance needs

improvement at 84.6%, compared to all

CoC-approved programs’ norm of 90.7%.

Regional Lymph Nodes in Surgically Resected Patients


96949290888684828078

85.7

88.390.1

AJH PA All CoC

At least 12 regional lymph nodes are

removed and pathologically examined for

resected colon cancer. The compliance

rate for Abington – Jefferson Health’s

compliance at 85.7% needs improvement,


norm of 90.1%.

CP3R and AJH’s Performance for Rectal Cancer

Radiation Therapy in Rectal Carcinomas


100908070605040302010

40.0

92.487.8

AJH PA All CoC

Radiation therapy is considered or

administered within six months of diagnosis

for patients under age 80 with clinical

or pathologic AJCC T4N0M0 or Stage III

receiving surgical resection for rectal

cancer. Abington – Jefferson Health’s

compliance with this standard at

40% reflects the chemotherapy arm

randomization in clinical trial participation,


norm of 87.8%.

CP3R and AJH’s Performance for Non-Small Cell Lung Cancer

Surgery is not First Course of Treatment for Non-Small Cell Lung Cancer That Has Not Spread to Distant Organs or Areas


Chemotherapy in Lymph Node Positive Non-Small Cell Lung Cancer


CP3R and AJH’s Performance for Gastric Cancer

Lymph Nodes in Surgically Resected Gastric Cancer

Percentage of All Cases60565248444036322824

54.256.7

41.2

AJH PA All CoC

At least 15 regional lymph nodes are

removed and pathologically examined

for resected gastric cancer. Abington –

Jefferson Health’s compliance with this

standard is 54.2%, favorable compared

to the CoC compliance rate of 41.2%.

100989694929088868482

100.0

97.4

92.3

AJH PA All CoC

Chemotherapy administered within four

months to day preoperatively or day of

surgery to six months postoperatively,

or it is considered for surgically resected

cases with pathologic, lymph node positive

NonSmall Cell Lung Cancer. Abington –

Jefferson Health’s compliance is 100%

compared to the CoC average of 92.3%.

100989694929088868482

90.992.8 92.7

AJH PA All CoC

This quality measure examines whether

surgery was used within the first course

of treatment for NonSmall Cell Lung

Cancer that has not spread to other organs.


rate of 90.9% is below the CoC standard

rate of 92.7%.

Quality Indicators

sixteen

Abington Hospital – Jefferson Health

1200 Old York Road • Abington, PA 19001

Jefferson.edu/AbingtonCancer

CS 17-0558

the rosenfeld cancer center at abington hospital ... · cancer research the rosenfeld cancer center...

Documents